Zobrazeno 1 - 10
of 265
pro vyhledávání: '"MESH : Lung Neoplasms"'
Autor:
Sonia Priou, Guillaume Lamé, Gérard Zalcman, Marie Wislez, Romain Bey, Gilles Chatellier, Jacques Cadranel, Xavier Tannier, Laurent Zelek, Christel Daniel, Christophe Tournigand, Emmanuelle Kempf
Publikováno v:
European Journal of Cancer
European Journal of Cancer, Elsevier, 2022, 173, pp.33-40. ⟨10.1016/j.ejca.2022.06.018⟩
European Journal of Cancer, Elsevier, 2022, 173, pp.33-40. ⟨10.1016/j.ejca.2022.06.018⟩
International audience; IntroductionThe SARS-CoV-2 pandemic has impacted the care of cancer patients. This study sought to assess the pandemic’s impact on the clinical presentations and outcomes of newly referred patients with lung cancer from the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f7e8943f23d2050fd39877db1d949104
https://doi.org/10.1016/j.ejca.2022.06.018
https://doi.org/10.1016/j.ejca.2022.06.018
Autor:
Alice Mogenet, Fabrice Barlesi, Benjamin Besse, Stefan Michiels, Maryam Karimi, Alicia Tran-Dien, Nicolas Girard, Julien Mazieres, Clarisse Audigier-Valette, Myriam Locatelli-Sanchez, Maud Kamal, Pierre Gestraud, Abderaouf Hamza, Alexandra Jacquet, Marta Jimenez, Sabrina Yara, Laurent Greillier, François Bertucci, David Planchard, Jean-Charles Soria, Ivan Bieche, Pascale Tomasini
Publikováno v:
Lung Cancer
Lung Cancer, 2022, 169, pp.31-39. ⟨10.1016/j.lungcan.2022.05.004⟩
Lung Cancer, 2022, 169, pp.31-39. ⟨10.1016/j.lungcan.2022.05.004⟩
Lung cancer remains the most frequent cause of brain metastases (BMs) and is responsible for high morbidity and mortality. Intracranial response to systemic treatments is inconsistent due to several mechanisms: genomic heterogeneity, blood-tumor barr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cc0515e216ca1aadab56d391da8b8038
https://doi.org/10.1016/j.lungcan.2022.05.004
https://doi.org/10.1016/j.lungcan.2022.05.004
Autor:
Nicolas Giraud, Claire Meynard, Catherine Durdux, Audrey Mansuet-Lupo, Armelle Guénégou-Arnoux, Diane Damotte, Geoffroy Boulle, P. Giraud, Paul Imbault, Antonio Bobbio
Publikováno v:
Practical Radiation Oncology: An official journal of the American Society for Radiation Oncology
Practical Radiation Oncology: An official journal of the American Society for Radiation Oncology, Elsevier, 2021, 11 (6), pp.491-501. ⟨10.1016/j.prro.2021.05.006⟩
Practical Radiation Oncology: An official journal of the American Society for Radiation Oncology, Elsevier, 2021, 11 (6), pp.491-501. ⟨10.1016/j.prro.2021.05.006⟩
International audience; Purpose: Radiation therapy for locally advanced non-small cell lung cancer (NSCLC) should treat the whole tumor, including its microscopic extensions, and protect adjacent organs at risk as much as possible. The aim of our stu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0b5b45c4f686edd28c84d8efd46cb245
https://doi.org/10.1016/j.prro.2021.05.006
https://doi.org/10.1016/j.prro.2021.05.006
Autor:
John Wrangle, Ticiana Leal, Gilles Robinet, Neal Ready, David Maag, Jyoti Malhotra, Melissa Lynne Johnson, Satwant Lally, Petros Nikolinakos, Jyoti D. Patel, Daniel Morgensztern, Benjamin Besse, Vincent Blot, Giuseppe Curigliano, Ricardo Valenzuela, Laurent Greillier, Jonathan M. Lehman
Publikováno v:
Journal of Thoracic Oncology
Journal of Thoracic Oncology, 2021, 16 (9), pp.1559-1569. ⟨10.1016/j.jtho.2021.02.022⟩
Journal of Thoracic Oncology, 2021, 16 (9), pp.1559-1569. ⟨10.1016/j.jtho.2021.02.022⟩
Introduction This open-label, phase 1–2 study evaluated the safety and efficacy of rovalpituzumab tesirine (Rova-T), an antibody-drug conjugate targeting DLL3, plus immune checkpoint inhibitors nivolumab plus or minus ipilimumab in previously treat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a7c2323534cecd409bf8ef57951bfa24
https://doi.org/10.1016/j.jtho.2021.02.022
https://doi.org/10.1016/j.jtho.2021.02.022
Autor:
Frédérique Penault-Llorca, Keith M. Kerr, Pilar Garrido, Erik Thunnissen, Elisabeth Dequeker, Nicola Normanno, Simon J. Patton, Jenni Fairley, Joshua Kapp, Daniëlle de Ridder, Aleš Ryška, Holger Moch
Publikováno v:
Virchows Archiv
Virchows Archiv, Springer Verlag, 2022, 481 (3), pp.351-366. ⟨10.1007/s00428-022-03344-1⟩
Virchows Archiv, Springer Verlag, 2022, 481 (3), pp.351-366. ⟨10.1007/s00428-022-03344-1⟩
The diagnostic work-up for non-small cell lung cancer (NSCLC) requires biomarker testing to guide therapy choices. This article is the second of a two-part series. In Part 1, we summarised evidence-based recommendations for obtaining and processing s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8aed38045505930a53d70ad5567d02ab
https://hal.archives-ouvertes.fr/hal-03857030
https://hal.archives-ouvertes.fr/hal-03857030
Autor:
Filleron, Thomas, Bachelier, Marine, Mazieres, Julien, Pérol, Maurice, Meyer, Nicolas, Martin, Elodie, Mathevet, Fanny, Dauxois, Jean-Yves, Porcher, Raphaël, Delord, Jean-Pierre
Publikováno v:
JAMA Network Open
JAMA Network Open, 2021, 4 (12), pp.e2139573. ⟨10.1001/jamanetworkopen.2021.39573⟩
JAMA Network Open, 2021, 4 (12), pp.e2139573. ⟨10.1001/jamanetworkopen.2021.39573⟩
International audience; ImportanceCompared with standard cytotoxic therapies, randomized immune checkpoint inhibitor (ICI) phase 3 trials reveal delayed benefits in terms of patient survival and/or long-term response. Such outcomes generally violate
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______1398::2cba5cacb81de819c5077ec65e762a0b
https://hal.science/hal-03842894/document
https://hal.science/hal-03842894/document
Autor:
Fabrice Barlesi, Laure Deyme, Diane-Charlotte Imbs, Elissa Cousin, Mathieu Barbolosi, Sylvanie Bonnet, Pascale Tomasini, Laurent Greillier, Melissa Galloux, Albane Testot-Ferry, Annick Pelletier, Nicolas André, Joseph Ciccolini, Dominique Barbolosi
Publikováno v:
Cancer Chemotherapy and Pharmacology
Cancer Chemotherapy and Pharmacology, 2022, 90 (2), pp.149-160. ⟨10.1007/s00280-022-04455-x⟩
Cancer Chemotherapy and Pharmacology, 2022, 90 (2), pp.149-160. ⟨10.1007/s00280-022-04455-x⟩
A phase Ia/Ib trial of metronomic oral vinorelbine (MOV) driven by a mathematical model was performed in heavily pretreated metastatic Non-Small Cell Lung Cancer or Pleural Mesothelioma patients. Disease Control Rate, progression free survival, toxic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2f34379e61159ac5c5cbc8be9e082bc3
https://inria.hal.science/hal-03923667
https://inria.hal.science/hal-03923667
Autor:
Sara Pilotto, Alice Avancini, Jessica Menis, Isabella Sperduti, Matteo Giaj Levra, Thierry Berghmans, Paolo Bironzo, Mariana Brandão, Dirk De Ruysscher, John Edwards, Corinne Faivre-Finn, Nicolas Girard, Laurent Greillier, Lizza Hendriks, Sylvie Lantuejoul, Murielle Mauer, Silvia Novello, Mary O'Brien, Martin Reck, Noemi Reguart, Jordi Remon, Jan von der Thüsen, Anne-Marie C. Dingemans, Benjamin Besse, Michele Milella
Publikováno v:
Lung Cancer
Lung Cancer, 2022, 169, pp.94-101. ⟨10.1016/j.lungcan.2022.05.009⟩
Lung Cancer, 169, 94-101. Elsevier Ireland Ltd
Lung Cancer, 2022, 169, pp.94-101. ⟨10.1016/j.lungcan.2022.05.009⟩
Lung Cancer, 169, 94-101. Elsevier Ireland Ltd
Objectives: Exercise has been reported to alleviate disease as well as treatment impact in patients with lung cancer. Nevertheless, there is limited information available regarding the perception of lung cancer dedicated healthcare professionals’ a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6d19adb701f993046199722af9bdbbe5
https://hal.science/hal-03925487
https://hal.science/hal-03925487
Autor:
Etienne Gouton, Nausicaa Malissen, Nicolas André, Arnaud Jeanson, Annick Pelletier, Albane Testot-Ferry, Caroline Gaudy-Marqueste, Laetitia Dahan, Emeline Tabouret, Thomas Chevalier, Laurent Greillier, Pascale Tomasini
Publikováno v:
Current Oncology
Current Oncology, 2022, 29 (3), pp.1902-1918. ⟨10.3390/curroncol29030155⟩
Current Oncology; Volume 29; Issue 3; Pages: 1902-1918
Current Oncology, 2022, 29 (3), pp.1902-1918. ⟨10.3390/curroncol29030155⟩
Current Oncology; Volume 29; Issue 3; Pages: 1902-1918
International audience; Background: Cancer therapies targeting actionable molecular alterations (AMA) have developed, but the clinical routine impact of high-throughput molecular profiling remains unclear. We present a monocentric experience of molec
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9befe06864165b58d63fbf8880383f09
https://hal.science/hal-03925589/document
https://hal.science/hal-03925589/document
Autor:
Julien Mazieres, Claire Lafitte, Charles Ricordel, Laurent Greillier, Elodie Negre, Gérard Zalcman, Charlotte Domblides, Jeannick Madelaine, Jaafar Bennouna, Céline Mascaux, Denis Moro-Sibilot, François Pinquie, Alexis B. Cortot, Josiane Otto, Jacques Cadranel, Alexandra Langlais, Franck Morin, Virginie Westeel, Benjamin Besse
Publikováno v:
Journal of Clinical Oncology
Journal of Clinical Oncology, 2022, 40 (7), pp.719-728. ⟨10.1200/JCO.21.01455⟩
Journal of Clinical Oncology, 2022, 40 (7), pp.719-728. ⟨10.1200/JCO.21.01455⟩
PURPOSE HER2 exon 20 insertions and point mutations are oncogenic drivers found in 1%-2% of patients with non–small-cell lung cancer (NSCLC). No targeted therapy is approved for this subset of patients. We prospectively evaluated the effectiveness
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ba5e269f82f648e89333d7473fc50216
https://hal.science/hal-03925605
https://hal.science/hal-03925605